Tirdzniecība Angion Biomedica Corp. - ANGN CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.0810 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 0.4887 |
| Atvērt* | 0.5279 |
| Izmaiņas par 1 gadu* | -72.36% |
| Dienas Diapazons* | 0.5242 - 0.5372 |
| 52 ned Diapazons | 0.46-2.41 |
| Vidējais apjoms (10 dienas) | 28.11K |
| Vidējais apjoms (3 mēneši) | 1.42M |
| Tirgus Kapitalizācija | 14.76M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 30.11M |
| Ieņēmumi | 2.30M |
| EPS | -1.29 |
| Dividende (Ienesīgums %) | N/A |
| Beta | -100.00K |
| Nākamās Peļņas Datums | Mar 28, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 0.4887 | 0.0096 | 2.00% | 0.4791 | 0.4890 | 0.4791 |
| Mar 21, 2023 | 0.4789 | 0.0248 | 5.46% | 0.4541 | 0.4791 | 0.4493 |
| Mar 20, 2023 | 0.4881 | 0.0001 | 0.02% | 0.4880 | 0.4986 | 0.4739 |
| Mar 17, 2023 | 0.4887 | -0.0490 | -9.11% | 0.5377 | 0.5378 | 0.4823 |
| Mar 16, 2023 | 0.5081 | 0.0198 | 4.05% | 0.4883 | 0.5695 | 0.4883 |
| Mar 15, 2023 | 0.4930 | -0.0542 | -9.90% | 0.5472 | 0.5671 | 0.4888 |
| Mar 14, 2023 | 0.5372 | -0.0196 | -3.52% | 0.5568 | 0.5963 | 0.5372 |
| Mar 13, 2023 | 0.5377 | -0.0240 | -4.27% | 0.5617 | 0.5621 | 0.5208 |
| Mar 10, 2023 | 0.5132 | -0.0641 | -11.10% | 0.5773 | 0.5778 | 0.5054 |
| Mar 9, 2023 | 0.5568 | -0.0604 | -9.79% | 0.6172 | 0.6256 | 0.5375 |
| Mar 8, 2023 | 0.5960 | 0.0078 | 1.33% | 0.5882 | 0.6158 | 0.5882 |
| Mar 7, 2023 | 0.6060 | -0.0094 | -1.53% | 0.6154 | 0.6155 | 0.6056 |
| Mar 6, 2023 | 0.6256 | -0.0208 | -3.22% | 0.6464 | 0.6466 | 0.6079 |
| Mar 3, 2023 | 0.6156 | 0.0290 | 4.94% | 0.5866 | 0.6258 | 0.5865 |
| Mar 2, 2023 | 0.5969 | 0.0009 | 0.15% | 0.5960 | 0.6130 | 0.5960 |
| Mar 1, 2023 | 0.5883 | -0.0370 | -5.92% | 0.6253 | 0.6256 | 0.5855 |
| Feb 28, 2023 | 0.6258 | 0.0006 | 0.10% | 0.6252 | 0.6452 | 0.6252 |
| Feb 27, 2023 | 0.6453 | 0.0001 | 0.02% | 0.6452 | 0.6454 | 0.6451 |
| Feb 24, 2023 | 0.6455 | 0.0006 | 0.09% | 0.6449 | 0.6736 | 0.6264 |
| Feb 23, 2023 | 0.6449 | -0.0001 | -0.02% | 0.6450 | 0.6454 | 0.6367 |
Angion Biomedica Corp. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Kopējie ienākumi | 28.312 | 2.88 | 1.487 | 4.029 |
| Ienākumi | 28.312 | 2.88 | 1.487 | 4.029 |
| Cost of Revenue, Total | 0.433 | 1.19 | 0.64 | 0.378 |
| Bruto Peļņa | 27.879 | 1.69 | 0.847 | 3.651 |
| Kopējie Darbības Izdevumi | 66.714 | 58.153 | 40.078 | 18.371 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 18.488 | 17.986 | 9.601 | 5.391 |
| Pētniecība un Attīstība | 48.698 | 38.977 | 29.837 | 12.602 |
| Darbības Izdevumi | -38.402 | -55.273 | -38.591 | -14.342 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -2.191 | -8.249 | 0.488 | 0.401 |
| Citi, Neto | -13.98 | -16.527 | -2.555 | -6.084 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -54.573 | -80.107 | -40.658 | -20.025 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -54.573 | -80.107 | -40.658 | -20.025 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -54.573 | -80.107 | -40.658 | -20.025 |
| Neto Ienākumi | -54.573 | -80.107 | -40.658 | -20.025 |
| Total Adjustments to Net Income | 0 | -4.98 | ||
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -54.573 | -80.107 | -40.658 | -25.005 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -54.573 | -80.107 | -40.658 | -25.005 |
| Atšķaidītie Neto Ienākumi | -54.573 | -80.107 | -40.658 | -25.005 |
| Atšķaidītie Ienākumi par Akcijām | 28.2448 | 14.7621 | 9.97635 | 9.97635 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -1.93214 | -5.42652 | -4.07544 | -2.50643 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Atšķaidītā Normalizētā Peļņa par Akciju | -1.96418 | -5.4226 | -4.07544 | -2.50643 |
| Gain (Loss) on Sale of Assets | 0 | -0.058 | ||
| Neparedzēti Izdevumi (Ienākumi) | -0.905 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 1.648 | 25.941 | 1.46 | 0.54 | 0.371 |
| Ienākumi | 1.648 | 25.941 | 1.46 | 0.54 | 0.371 |
| Cost of Revenue, Total | 0.433 | 0 | 0 | 0 | |
| Bruto Peļņa | 25.508 | 1.46 | 0.54 | 0.371 | |
| Kopējie Darbības Izdevumi | 16.133 | 11.307 | 17.218 | 17.879 | 20.31 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 4.466 | 4.206 | 3.93 | 4.34 | 6.012 |
| Pētniecība un Attīstība | 11.667 | 6.668 | 13.288 | 14.444 | 14.298 |
| Darbības Izdevumi | -14.485 | 14.634 | -15.758 | -17.339 | -19.939 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.206 | -0.016 | -0.074 | 0.067 | -2.168 |
| Citi, Neto | 0.039 | 0.272 | 0.128 | 0.2 | -14.58 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Neto Ienākumi | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Atšķaidītie Neto Ienākumi | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Atšķaidītie Ienākumi par Akcijām | 29.9592 | 29.9654 | 29.8296 | 29.6703 | 23.4438 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.47531 | 0.49691 | -0.52646 | -0.57539 | -1.56489 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.47531 | 0.49691 | -0.52646 | -0.60589 | -1.56489 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | 0 | -0.905 | ||
| Gain (Loss) on Sale of Assets | 0 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 91.247 | 42.297 | 6.106 | 25.679 |
| Nauda un Īstermiņa Ieguldījumi | 88.756 | 34.607 | 5.571 | 25.512 |
| Nauda un Ekvivalenti | 88.756 | 34.607 | 5.571 | 25.512 |
| Debitoru Parādu Kopsumma, Neto | 0.806 | 5 | 0.44 | 0.107 |
| Prepaid Expenses | 1.031 | 0.352 | 0.095 | 0.06 |
| Total Assets | 96.513 | 47.347 | 11.886 | 26.628 |
| Property/Plant/Equipment, Total - Net | 4.437 | 4.228 | 4.781 | 0.017 |
| Property/Plant/Equipment, Total - Gross | 4.954 | 4.654 | 5.109 | 0.295 |
| Accumulated Depreciation, Total | -0.517 | -0.426 | -0.328 | -0.278 |
| Long Term Investments | 0.723 | 0.822 | 0.999 | 0.932 |
| Total Current Liabilities | 11.296 | 107.449 | 26.575 | 7.355 |
| Accounts Payable | 4.71 | 5.578 | 11.239 | 0.534 |
| Accrued Expenses | 4.113 | 7.276 | 3.694 | 2.98 |
| Notes Payable/Short Term Debt | 0 | 51.43 | 5.848 | 0 |
| Other Current Liabilities, Total | 2.415 | 43.165 | 5.794 | 3.841 |
| Total Liabilities | 15.006 | 137.796 | 30.472 | 7.717 |
| Total Long Term Debt | 0.235 | 0.635 | 0 | 0 |
| Other Liabilities, Total | 3.475 | 29.712 | 3.897 | 0.362 |
| Total Equity | 81.507 | -90.449 | -18.586 | 18.911 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | |
| Common Stock | 0.3 | 0.156 | 0.095 | 0.094 |
| Additional Paid-In Capital | 296.445 | 72.136 | 63.584 | 60.138 |
| Retained Earnings (Accumulated Deficit) | -215.135 | -160.562 | -80.455 | -39.797 |
| Treasury Stock - Common | 0 | -1.846 | -1.81 | -1.524 |
| Total Liabilities & Shareholders’ Equity | 96.513 | 47.347 | 11.886 | 26.628 |
| Total Common Shares Outstanding | 29.9591 | 15.3167 | 9.97635 | 9.97635 |
| Other Current Assets, Total | 0.654 | 2.338 | ||
| Long Term Debt | 0 | 0.635 | ||
| Other Equity, Total | -0.103 | -0.333 | ||
| Other Long Term Assets, Total | 0.106 | |||
| Current Port. of LT Debt/Capital Leases | 0.058 | |||
| Capital Lease Obligations | 0.235 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 76.239 | 91.247 | 104.393 | 119.702 | 133.498 |
| Nauda un Īstermiņa Ieguldījumi | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
| Nauda un Ekvivalenti | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
| Debitoru Parādu Kopsumma, Neto | 0 | 0.806 | 0 | 0 | 0 |
| Prepaid Expenses | 0.021 | 1.031 | 1.018 | 1.761 | 2.343 |
| Other Current Assets, Total | 3.216 | 0.654 | 0.639 | 0.628 | 0.699 |
| Total Assets | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
| Property/Plant/Equipment, Total - Net | 4.209 | 4.437 | 4.652 | 4.776 | 4.787 |
| Property/Plant/Equipment, Total - Gross | 4.758 | 4.954 | 5.137 | 5.231 | 5.219 |
| Accumulated Depreciation, Total | -0.549 | -0.517 | -0.485 | -0.455 | -0.432 |
| Long Term Investments | 0.732 | 0.723 | 0.862 | 0.843 | 0.877 |
| Other Long Term Assets, Total | 0.078 | 0.106 | 0.033 | 0.038 | 0.038 |
| Total Current Liabilities | 10.381 | 11.296 | 17.946 | 20.524 | 16.963 |
| Accounts Payable | 3.433 | 4.71 | 7.679 | 9.307 | 6.69 |
| Accrued Expenses | 6.16 | 4.113 | 6.219 | 5.522 | 4.872 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0.895 |
| Other Current Liabilities, Total | 0.728 | 2.415 | 4.048 | 5.695 | 4.506 |
| Total Liabilities | 14.056 | 15.006 | 45.426 | 48.17 | 46.757 |
| Total Long Term Debt | 0.219 | 0.235 | 0 | 0 | 0 |
| Long Term Debt | 0 | 0 | 0 | 0 | |
| Other Liabilities, Total | 3.456 | 3.475 | 27.48 | 27.646 | 29.794 |
| Total Equity | 67.202 | 81.507 | 64.514 | 77.189 | 92.443 |
| Common Stock | 0.3 | 0.3 | 0.304 | 0.303 | 0.3 |
| Additional Paid-In Capital | 296.476 | 296.445 | 298.518 | 295.636 | 292.67 |
| Retained Earnings (Accumulated Deficit) | -229.375 | -215.135 | -230.025 | -214.321 | -197.249 |
| Treasury Stock - Common | 0 | -4.21 | -4.21 | -2.991 | |
| Other Equity, Total | -0.199 | -0.103 | -0.073 | -0.219 | -0.287 |
| Total Liabilities & Shareholders’ Equity | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
| Total Common Shares Outstanding | 29.9594 | 29.9591 | 29.9331 | 29.7976 | 29.6605 |
| Current Port. of LT Debt/Capital Leases | 0.06 | 0.058 | |||
| Capital Lease Obligations | 0.219 | 0.235 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -54.573 | -80.107 | -40.658 | -20.025 |
| Nauda no Darbības | -52.643 | -22.888 | -24.589 | -8.02 |
| Nauda no Darbības | 0.091 | 0.098 | 0.05 | 0.002 |
| Bezskaidras Naudas Preces | 27.809 | 31.352 | 6.269 | 9.051 |
| Cash Taxes Paid | 0 | 0 | ||
| Samaksātie Procenti Naudā | 0.007 | 0 | 0 | |
| Izmaiņas Apgrozāmajā Kapitālā | -25.97 | 25.769 | 9.75 | 2.952 |
| Nauda no Ieguldījumu Darbībām | -0.382 | -0.041 | -0.242 | 0 |
| Kapitālie Izdevumi | -0.382 | -0.041 | -0.242 | 0 |
| Nauda no Darbībām ar Finansēšanu | 107.171 | 52.409 | 4.89 | 31.741 |
| Akciju Izsniegšana (Atkāpšanās), Neto | -0.617 | 20.813 | -0.375 | 28.596 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 0.293 | 32.118 | 5.265 | 3.145 |
| Neto Izmaiņas Naudā | 54.149 | 29.036 | -19.941 | 23.721 |
| Naudas Plūsma Finansēšanas Posteņos | 107.495 | -0.522 | ||
| Ārvalstu Valūtas Ietekme | 0.003 | -0.444 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.24 | -54.573 | -69.463 | -53.759 | -36.687 |
| Cash From Operating Activities | -15.653 | -52.643 | -38.281 | -23.082 | -12.551 |
| Cash From Operating Activities | 0.032 | 0.091 | 0.059 | 0.029 | 0.006 |
| Non-Cash Items | 0.179 | 27.809 | 25.729 | 23.505 | 21.675 |
| Changes in Working Capital | -1.624 | -25.97 | 5.394 | 7.143 | 2.455 |
| Cash From Investing Activities | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
| Capital Expenditures | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
| Cash From Financing Activities | -0.014 | 107.171 | 106.767 | 106.068 | 108.444 |
| Financing Cash Flow Items | 0 | 107.495 | -5.52 | -5.428 | -2.797 |
| Issuance (Retirement) of Stock, Net | 0 | -0.617 | 112.287 | 111.496 | 111.241 |
| Issuance (Retirement) of Debt, Net | -0.014 | 0.293 | 0 | 0 | 0 |
| Foreign Exchange Effects | -0.087 | 0.003 | -0.011 | 0.005 | -0.003 |
| Net Change in Cash | -15.754 | 54.149 | 68.129 | 82.706 | 95.849 |
| Cash Interest Paid | 0.007 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Satterfield (Thomas A Jr) | Individual Investor | 7.2983 | 2197825 | 623278 | 2022-12-31 | LOW |
| Vifor (International), Ltd | Corporation | 6.6269 | 1995643 | 0 | 2023-03-15 | LOW |
| EISA-ABC LLC | Corporation | 5.719 | 1722237 | 0 | 2023-03-15 | LOW |
| Goldberg (Itzhak D) | Individual Investor | 5.6193 | 1692199 | 4213 | 2023-03-15 | LOW |
| Venkatesan (Jay R) | Individual Investor | 3.9765 | 1197498 | 0 | 2023-03-15 | LOW |
| BVF Partners L.P. | Hedge Fund | 3.5574 | 1071297 | 0 | 2022-12-31 | LOW |
| Nantahala Capital Management, LLC | Hedge Fund | 3.4308 | 1033145 | -32867 | 2022-12-31 | MED |
| Ganzi (Victor F.) | Individual Investor | 3.25 | 978698 | 0 | 2023-03-15 | LOW |
| CM Management, LLC | Investment Advisor | 2.4313 | 732178 | 132178 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1386 | 644035 | 675 | 2022-12-31 | LOW |
| Park West Asset Management LLC | Hedge Fund | 1.2311 | 370724 | 0 | 2022-12-31 | MED |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.5811 | 175000 | 0 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5593 | 168436 | -451 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.4041 | 121700 | -87277 | 2022-12-31 | HIGH |
| Omenn (Gilbert S) | Individual Investor | 0.2667 | 80326 | 0 | 2023-03-15 | LOW |
| Millennium Management LLC | Hedge Fund | 0.2502 | 75342 | -50261 | 2022-12-31 | HIGH |
| Raymond James & Associates, Inc. | Research Firm | 0.1992 | 60000 | 0 | 2022-12-31 | LOW |
| Birchview Capital, LP | Investment Advisor | 0.1806 | 54392 | 0 | 2022-12-31 | LOW |
| Ergoteles Capital | Hedge Fund | 0.1757 | 52913 | -25944 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.1696 | 51069 | 1188 | 2022-12-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group500K+
Tirgotāji
92K+
Ikmēneša aktīvie klienti
$53M+
Ikmēneša ieguldījumu apjoms
$30M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Angion Biomedica Corp. Company profile
Par Angion Biomedica Corp.
Angion Biomedica Corp. ir vēlīnās stadijas biofarmācijas uzņēmums. Uzņēmums koncentrējas uz mazu molekulu terapijas līdzekļu atklāšanu, izstrādi un komercializāciju, lai risinātu akūtu orgānu traumu un fibrozes slimību problēmas. Uzņēmuma galvenais kandidātprodukts ir ANG-3777. Uzņēmuma izstrādes procesā ietilpst ANG-3070, rho kināze 2 (ROCK2) un CYP11B2. ANG-3777 ir hepatocītu augšanas faktora (HGF) mimetiķis, ko uzņēmums novērtē vairākiem akūtiem orgānu bojājumiem un saistītām indikācijām, tostarp akūtiem nieru bojājumiem (AKI) un citu orgānu, piemēram, plaušu, centrālās nervu sistēmas (CNS) un sirds bojājumiem. Uzņēmums novērtē ANG-3777 arī akūtu plaušu bojājumu (ALI) indikācijām, īpašu uzmanību pievēršot akūta elpošanas distresa sindromam (ARDS), kā arī akūtiem CNS bojājumiem. Citas uzņēmuma programmas ir saistītas ar fibrotisko slimību ārstēšanu, tirozīnkināzes inhibitoru (TKI) ANG-3070 un rho kināzes 2 (ROCK2) inhibitoru.
| Industry: | Biotechnology & Medical Research (NEC) |
7-57 Wells Avenue
NEWTON
MASSACHUSETTS 02459
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com